All Stories

  1. Impact of discordance between patient’s and evaluator’s global assessment on treatment outcomes in 14 868 patients with spondyloarthritis
  2. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment—results from 12 countries in EuroSpA
  3. Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible
  4. Golimumab in the treatment of psoriatic arthritis
  5. Treatment as Prevention for Hepatitis C (TraP Hep C) – a nationwide elimination programme in Iceland using direct‐acting antiviral agents
  6. Infections and the risk of psoriatic arthritis among psoriasis patients: a systematic review
  7. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study
  8. Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis
  9. The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study
  10. Treatment as Prevention for Hepatitis C (TraP HepC). A Real-world Experience from the First 12 Months of a Nationwide Elimination Program in Iceland
  11. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries
  12. Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis
  13. Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study
  14. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
  15. Treatments for Nail Psoriasis: A Systematic Review by the GRAPPA Nail Psoriasis Work Group
  16. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study
  17. Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network
  18. Risk for Cardiovascular Disease Early and Late After a Diagnosis of Giant-Cell Arteritis
  19. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study
  20. Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study
  21. Prevalence and treatment patterns of psoriatic arthritis in the UK
  22. Psoriatic Arthritis and Onycholysis — Results from the Cross-sectional Reykjavik Psoriatic Arthritis Study
  23. Obesity and the risk of psoriatic arthritis: a population-based study
  24. Re: Risk of malignancy associated with Lyme disease: Still up in the air
  25. Borrelia and subsequent risk of solid tumors and hematologic malignancies in Sweden
  26. Prevalence of the Metabolic Syndrome in Psoriasis
  27. Validation of Psoriatic Arthritis Diagnoses in Electronic Medical Records Using Natural Language Processing
  28. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis
  29. Small joint involvement in psoriatic arthritis is associated with onycholysis: the Reykjavik Psoriatic Arthritis Study
  30. A ‘pilot’ study on air-travel and venous thromboembolism
  31. The relationship between cancer and rheumatoid arthritis: still a large research agenda
  32. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8+ T cells